SPONSOR

Ruijin Hospital

Total Trials

Recruiting

Phases

Phase 2, EARLY_Phase 1, Phase 4, Phase 1, Phase 3

Conditions studied: CNS Lymphoma Sarcoma Relapsed/Refractory B Cell-Mediated Autoimmune Diseases Recurrent Adult Acute Myeloid Leukemia Myelodysplastic Syndrome Adult Acute Myeloid Leukemia Pancreatic Neoplasms Hepatic Metastasis of Pancreatic Cancer Cervical Cancer Chemoradiotherapy

Ruijin Hospital is a clinical research sponsor with 28 registered studies on ClinicalTrials.gov, of which 28 are actively recruiting participants. Research covers conditions including CNS Lymphoma, Sarcoma, Relapsed/Refractory B Cell-Mediated Autoimmune Diseases, Recurrent Adult Acute Myeloid Leukemia.

The trial portfolio spans Phase 2, EARLY_Phase 1, Phase 4 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.

Frequently Asked Questions — Ruijin Hospital

How many clinical trials has Ruijin Hospital sponsored?

ClinicalMetric currently tracks 28 clinical trials sponsored by Ruijin Hospital, of which 28 are actively recruiting participants. These trials cover conditions including CNS Lymphoma, Sarcoma, Relapsed/Refractory B Cell-Mediated Autoimmune Diseases. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.

What therapeutic areas does Ruijin Hospital research focus on?

Ruijin Hospital clinical trials span CNS Lymphoma, Sarcoma, Relapsed/Refractory B Cell-Mediated Autoimmune Diseases, Recurrent Adult Acute Myeloid Leukemia, Myelodysplastic Syndrome, and additional conditions. The research pipeline includes Phase 2, EARLY_Phase 1, Phase 4 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.

How do I participate in a Ruijin Hospital clinical trial?

To participate in a Ruijin Hospital trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Ruijin Hospital trials with current recruitment status updated daily.

Ruijin Hospital

Frequently Asked Questions — Ruijin Hospital

Clinical Trials by Ruijin Hospital

Relma-cel Followed by Tislelizumab for the Treatment of Relapsed/Refractory CNS Large B-Cell Lymphoma

BIOmarker Driven Trial of VEGFR2 Inhibitor in Advanced or Metastatic Sarcoma

Safety and Efficacy Study of RXIM002 in Severe, Relapsed or Refractory Autoimmune Diseases

A Prospective, Multicenter, and Exploratory Study of CMGV in the Treatment of Recurrent Adult AML and MDS-EB-2/Elder AML

Hepatic Arterial Infusion of Sodium Bicarbonate (NaHCO3) Combined With NASOX Regimen and Programmed Death-1 (PD-1) Inhibitors for Pancreatic Cancer Liver Metastases

Toripalimab Combined With Definitive CCRT for LACC Patients

AI System for Anatomic Recognition & Lesion Detection in Nasopharyngolaryngoscopy: A Prospective Study

A Trial on the Recurrence Free Survival Rate of Type I AIP With High-risk of Recurrence

A Study of LCAR-HL30 in Subjects With Relapsed/Refractory Hodgkin's Lymphoma and Anaplastic Large Cell Lymphoma

The Role of 18F-FDG&amp;68Ga-FAPI PET/CT in the Assessment of Conversion Therapy Efficacy in Gastric Cancer with Peritoneal Metastasis.

A Prospective Clinical Study on Reduced-intensity Radiotherapy for Stage I/II Low-risk Nasal-type NK/T-cell Lymphoma Achieving Complete Remission After Chemotherapy

The Application Value of 68Ga-grazytracer PET in Immunotherapy for Stage III Non-small-cell Lung Cancer

Shanghai At Risk for Alzheimer's Disease: a Cohort Study

Immunobridging/Maintenance Therapy Versus Non-bridging Therapy in CAR-T Therapy for Low-risk R/R B-NHL

The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Gastrointestinal Malignancies

The Role of 18F-FDG and 68Ga-FAPI PET/CT in the Diagnosis and the Efficacy Evaluation of Advanced Colorectal Cancer (peritoneal Metastasis With/without Other Metastases)

Effect of Belimumab on Antibody Titers in Primary APS Patients

A Multicenter, Prospective, Real-world Study of a Regimen Containing Tucidinostat for Primary Treatment of DLBCL

Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment

An Exploratory Study of Personalized Cancer Vaccine in Adjuvant Therapy of Solid Tumors

a Feasibility Study of iHD-SRT for BM

The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Advanced Hepatobiliary Malignancy

Clinical Analysis of the Antihypertensive Effect of Laparoscopic Peripheral Nerve Blockade of the Renal Artery in Patients With Retroperitoneal Disease and Hypertension

A Study of Dose Escalation of ES502 in Patients With Advanced Pancreatic Cancer

A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL

An Organ Preservation Strategies After Chemoradiotherapy Combined With Immunotherapy for Esophageal Cancer (PALACE3).

CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic Factors

Risk Evaluation by COronary Imaging and Artificial intelliGence Based fuNctIonal analyZing tEchniques - III

The Role of 18F-FDG&68Ga-FAPI PET/CT in the Assessment of Conversion Therapy Efficacy in Gastric Cancer with Peritoneal Metastasis.